Head-to-head · Cost-Efficiency Index
Ivy Rx vs Novi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ivy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxNovi
Shoppers drawn to the lowest flat headline price in this batch, if they're comfortable that dosing, coverage states, and pharmacy details aren't published anywhere on the site.
Visit NoviThe verdict
Ivy Rx and Novi tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Ivy Rx (ranked #102, a hair above #105) — Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms. But Novi is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Ivy Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ivy Rx | Novi |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $97/mo (microdose tier, promotional rate, compounded) | $99/mo (all doses, promotional rate, compounded) |
| Tirzepatide / mo | $199/mo (brand Mounjaro, compounded) | $133/mo (all doses, promotional rate, compounded) |
| Semaglutide / yr (modeled) | $1,164 | $1,188 |
| Tirzepatide / yr (modeled) | $2,388 | $1,596 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #102 | #105 |
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
Novi
69/100Where the value is
- Lowest advertised entry price in this entire batch for both drugs ($99 semaglutide / $133 tirzepatide)
- LegitScript certified, independently verifiable via the linked legitscript.com record
- States one flat price per dose with no separate visit fee and free shipping
The tradeoffs
- No published mg dose, supply duration, state-coverage list, named medical director, or named compounding pharmacy anywhere on the site or its help center — the least transparent operational disclosure of any company researched in this batch
- The advertised $99/$133 rate is displayed against a live countdown timer ('price increases in...') next to a claimed $299 original price, a scarcity tactic that makes it unclear whether this is a genuine standing rate or a recurring promotional one
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.